F. Grenoble, All lymphocytosis were superior to 3

/. , All experiments were performed with PBMC containing as a mean 80% of MCL cells. All patients provided written informed consent, validated by the Ethics Committee from the Avicenne Hospital in accordance with the Declaration of Helsinki. Patients usually received treatment shortly after sampling which made challenging to repeat experiments on samples of the same patient. Granta-519, Jeko-1, Maver, and HEK293T cell lines were purchased from the German Collection of Microorganisms and Cell Cultures, For patients with low lymphocytosis (<10.10 9 /L) B cells were purified by negative selection using RosetteSep kit (Stemcell technologies

, Cell culture and reagents

, Patients' cells were cryopreserved in liquid nitrogen in the presence of 10% dimethyl sulfoxide and 20% heatinactivated fetal calf serum (FCS) at Avicenne Hospital. MCL leukemic cells (3 × 10 6 cells/mL) and Granta-519, Jeko-1, Maver or HEK293T cells (1 × 10 6 cells/mL) were cultured in RPMI 1640 medium supplemented with 10%

B. Gibco and T. Scientific, For BCR stimulation soluble F(ab') 2 fragment of donkey antihuman IgM antibody (10 µg/mL; Jackson ImmunoResearch, Interchim, Monluçon, France) were used for the indicated periods of time, Cells were also treated with either Bortezomib (10 nM) (Janssen-Cilag, Issy-les-Moulineaux, France), Ibrutinib (PCI-32765) (100 nM-5 µM)

L. H. Argatoff, J. M. Connors, R. J. Klasa, D. E. Horsman, and R. D. Gascoyne, Mantle cell lymphoma: a clinicopathologic study of 80 cases, Blood, vol.89, pp.2067-78, 1997.

J. Orchard, R. Garand, Z. Davis, G. Babbage, S. Sahota et al., A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease, Blood, vol.101, pp.4975-81, 2003.

F. Bosch, P. Jares, E. Campo, A. Lopez-guillermo, M. A. Piris et al., PRAD-1/cyclin D1 gene overexpression in G

, chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma, Blood, vol.84, pp.2726-2758, 1994.

P. Jares, D. Colomer, and E. Campo, Molecular pathogenesis of mantle cell lymphoma, J Clin Invest, vol.122, pp.3416-3439, 2012.

P. Perez-galan, M. Dreyling, and A. Wiestner, Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era, Blood, vol.117, pp.26-38, 2011.

A. Hadzidimitriou, A. Agathangelidis, N. Darzentas, F. Murray, M. H. Delfau-larue et al., Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases, Blood, vol.118, pp.3088-95, 2011.

N. S. Saba, D. Liu, S. E. Herman, C. Underbayev, X. Tian et al., Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma, Blood, vol.128, pp.82-92, 2016.

E. G. Rizzatti, R. P. Falcao, R. A. Panepucci, R. Proto-siqueira, W. T. Anselmo-lima et al., Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways, Br J Haematol, vol.130, pp.516-542, 2005.

Y. Kimura, F. Arakawa, J. Kiyasu, H. Miyoshi, M. Yoshida et al., The Wnt signaling pathway and mitotic regulators in the initiation and evolution of mantle cell lymphoma: gene expression analysis, Int J Oncol, vol.43, pp.457-68, 2013.

P. Gelebart, M. Anand, H. Armanious, A. C. Peters, D. Bard et al., Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma, Blood, vol.112, pp.5171-5180, 2008.

H. Clevers and R. Nusse, Wnt/beta-catenin signaling and disease, Cell, vol.149, pp.1192-205, 2012.

K. M. Cadigan and R. Nusse, Wnt signaling: a common theme in animal development, Genes Dev, vol.11, pp.3286-305, 1997.

J. L. Stamos and W. I. Weis, The beta-catenin destruction complex, Cold Spring Harb Perspect Biol, vol.5, p.7898, 2013.

D. A. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B, Nature, vol.378, pp.785-794, 1995.

N. Goode, K. Hughes, J. R. Woodgett, and P. J. Parker, Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes, J Biol Chem, vol.267, pp.16878-82, 1992.

S. L. Christian, P. V. Sims, and M. R. Gold, The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3, J Immunol, vol.169, pp.758-69, 2002.

O. Tetsu and F. Mccormick, Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells, Nature, vol.398, pp.422-428, 1999.

T. C. He, A. B. Sparks, C. Rago, H. Hermeking, L. Zawel et al., Identification of c-MYC as a target of the APC pathway, Science, vol.281, pp.1509-1521, 1998.

E. H. Jho, T. Zhang, C. Domon, C. K. Joo, J. N. Freund et al.,

, Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway, Mol Cell Biol, vol.22, pp.1172-83, 2002.

K. M. Nicholson and N. G. Anderson, The protein kinase B/Akt signalling pathway in human malignancy, Cell Signal, vol.14, pp.381-95, 2002.

F. Baran-marszak, M. Boukhiar, S. Harel, C. Laguillier, C. Roger et al., Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, vol.95, pp.1865-72, 2010.

S. Bernard, D. Danglade, L. Gardano, C. Laguillier, G. Lazarian et al., Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma, Int J Cancer, vol.136, pp.2761-74, 2014.

M. R. Gold, R. J. Ingham, S. J. Mcleod, S. L. Christian, M. P. Scheid et al., Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase, Immunol Rev, vol.176, pp.47-68, 2000.

J. Dal-col and R. Dolcetti, GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma, Cell Cycle, vol.7, pp.2813-2819, 2008.

M. R. Gold, M. P. Scheid, L. Santos, M. Dang-lawson, R. A. Roth et al., The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase, J Immunol, vol.163, pp.1894-905, 1999.

M. A. Boukhiar, C. Roger, J. Tran, R. Gressin, A. Martin et al., Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma, Exp Hematol Oncol, vol.2, p.4, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00796142

M. K. Bognar, M. Vincendeau, T. Erdmann, T. Seeholzer, M. Grau et al., Oncogenic CARMA1 couples NF-kappaB and beta-catenin signaling in diffuse large B-cell lymphomas, Oncogene, vol.35, pp.4269-81, 2016.

F. E. Chen, D. B. Huang, Y. Q. Chen, and G. Ghosh, Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA, Nature, vol.391, pp.410-413, 1998.

J. A. Raskatov, J. L. Meier, J. W. Puckett, F. Yang, P. Ramakrishnan et al., Modulation of NF-kappaB-dependent gene transcription using programmable DNA minor groove binders, Proc Natl Acad Sci, vol.109, pp.1023-1031, 2012.

M. Lepourcelet, Y. N. Chen, D. S. France, H. Wang, P. Crews et al., Small-molecule antagonists of the oncogenic Tcf/betacatenin protein complex, Cancer Cell, vol.5, pp.91-102, 2004.

N. I. Khan, K. F. Bradstock, and L. J. Bendall, Activation of Wnt/betacatenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia, Br J Haematol, vol.138, pp.338-386, 2007.

R. K. Gandhirajan, S. J. Poll-wolbeck, I. Gehrke, and K. A. Kreuzer, Wnt/ beta-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options, Curr Cancer Drug Targets, vol.10, pp.716-743, 2010.

M. Spaargaren, M. F. De-rooij, A. P. Kater, and E. Eldering, BTK inhibitors in chronic leukemia: a glimpse to the future, Oncogene, vol.34, pp.2426-2462, 2015.

J. Lindvall and T. C. Islam, Interaction of Btk and Akt in B cell signaling, Biochem Biophys Res Commun, vol.293, pp.1319-1345, 2002.

M. F. De-rooij, A. Kuil, A. P. Kater, M. J. Kersten, S. T. Pals et al., Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy, Blood, vol.125, pp.2306-2315, 2015.

Y. Sun, J. Campisi, C. Higano, T. M. Beer, P. Porter et al., Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B, Nat Med, vol.18, pp.1359-68, 2012.

Y. Sun, D. Zhu, F. Chen, M. Qian, H. Wei et al., SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment, Oncogene, vol.35, pp.4321-4355, 2016.

M. Lovatt and M. J. Bijlmakers, Stabilisation of beta-catenin downstream of T cell receptor signalling, PLoS ONE, vol.5, p.12794, 2010.

T. Koopmans, R. Eilers, M. Menzen, A. Halayko, and R. Gosens, betacatenin directs nuclear Factor-kappaB p65 output via CREBbinding protein/p300 in human airway smooth muscle, Front Immunol, vol.8, p.1086, 2017.

B. Ma and M. O. Hottiger, Crosstalk between Wnt/beta-Catenin and NF-kappaB signaling pathway during Inflammation, Front Immunol, vol.7, p.378, 2016.

T. Valenta, G. Hausmann, and K. Basler, The many faces and functions of beta-catenin, EMBO J, vol.31, pp.2714-2750, 2012.

X. Zhang and J. Hao, Development of anticancer agents targeting the Wnt/beta-catenin signaling, Am J Cancer Res, vol.5, pp.2344-60, 2015.

R. Mathur, L. Sehgal, F. K. Braun, Z. Berkova, J. Romaguerra et al., Targeting Wnt pathway in mantle cell lymphomainitiating cells, J Hematol Oncol, vol.8, p.63, 2015.

R. M. Hallett, M. K. Kondratyev, A. O. Giacomelli, A. M. Nixon, A. Girgis-gabardo et al., Small molecule antagonists of the Wnt/ beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer, PLoS ONE, vol.7, p.33976, 2012.

J. Mazieres, L. You, B. He, Z. Xu, A. Y. Lee et al., Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis, Oncogene, vol.24, pp.5396-400, 2005.